目的 对2012-2016年西安市第一医院质子泵抑制剂（PPIs）的使用情况进行分析，为临床合理用药提供参考。方法 采用回顾性方法，对2012-2016年西安市第一医院PPIs的销售金额、用药频度（DDDs）、日均费用（DDC）和排序比（B/A）等进行统计分析。结果 2012-2016年，PPIs的销售金额呈逐年增长的趋势；门诊和住院患者PPIs的销售金额、DDDs整体呈增加趋势；口服PPIs的销售金额和DDDs分别占24.4%、71.3%；注射用PPIs的销售金额和DDDs占比分别为75.6%、28.7%；5年来销售金额排名前3位的是注射用泮托拉唑（40 mg）、注射用兰索拉唑和雷贝拉唑钠肠溶片；DDDs排名前3位的是兰索拉唑肠溶片、雷贝拉唑钠肠溶片和注射用泮托拉唑（40 mg）。奥美拉唑肠溶胶囊、兰索拉唑肠溶片和泮托拉唑肠溶胶囊的DDC在5年中均小于10元。注射用兰索拉唑和注射用泮托拉唑（40 mg）5年的B/A均小于1.00。消化科PPIs的用药金额始终为第1位。结论 西安市第一医院注射用泮托拉唑的用量相对较大，可能存在一定程度的过度用药和不合理用药。

Objective To analyze the application of proton pump inhibitors (PPIs) in Xi'an No. 1 Hospital from 2012 to 2016, and in order to provide reference for clinical rational use of drugs. Methods A retrospective survey was conducted to analyze consumption sum, frequency of drug use (DDDs), defined daily cost (DDC), and sequence ratio (B/A) of PPIs in Xi'an No. 1 Hospital from 2012 to 2016. Results Consumption sum of PPIs increased year by year from 2012 to 2016. Consumption sum and DDDs of outpatient and inpatient had a tendency of increase on the whole. Consumption sum and DDDs of oral PPIs accounted for 24.4% and 71.3%, while those of PPIs for injection accounted for 75.6% and 28.7%. The top three drugs in the list of consumption sum in 5 years were Pantoprazole for injection (40 mg), Lansoprazole for injection, and Rabeprazole Sodium Enteric-coated Tablets. DDDs of Lansoprazole Tablets, Pantoprazole for injection, and Rabeprazole Sodium Enteric-coated Tablets ranked top three. DDC of Omeprazole Enteric-coated Capsules, Lansoprazole Enteric-coated Tablets, and Pantoprazole Sodium Enteric-Coated Capsules in 5 years were lower than 10. B/A of Lansoprazole for injection and Pantoprazole for injection (40 mg) in 5 years were less than 1.00. Consumption sum of PPIs in Department of Gastroenterology ranked the first. Conclusion The usage of Lansoprazole for injection in Xi'an No. 1 Hospital is relatively large, and it may be some degree of excessive use and irrational use.